深入解读埃万妥单抗联合疗法的作用机制与协同效应。

*以下内容仅供医疗卫生专业人士浏览。

审批编码：CP-552513

批准分发日期：2025/11/25

有效期：2026/11/25

参考文献：

[1]中国医师协会多学科诊疗专业委员会，等. 原发性肺癌罕见靶点靶向治疗中国临床诊疗指南（2024版）. 中国肿瘤临床与康复，2024，31(5)：265-295.

[2]Yang JC, Lu S, Hayashi H, et al. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025;393(17):1681-1693.

[3]Cho BC, et al. Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications. Clin Lung Cancer. 2023;24(2):89-97.

[4]Moores SL, et al. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. Cancer Res. 2016;76(13):3942-3953.

[5]Vijayaraghavan S, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Mol Cancer Ther. 2020;19(10):2044-2056.

[6]Lee J, et al. Lazertinib: on the Way to Its Throne. Yonsei Med J. 2022;63(9):799-805.

*“医学界”力求所发表内容专业、可靠，但不对内容的准确性做出承诺；请相关各方在采用或以此作为决策依据时另行核查。